Clinical trials: Cancer Neck
Advanced Solid Tumors Cancer
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone and in combination with a PD-1 target agent or with a VEGF TKI.
- Trial name
- NCT04417465
- Testing
- ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
- Where
- 17 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- AbbVie
Treatment for Metastatic or Locally Advanced Cervical Cancer
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure.
- Trial name
- NCT01613677
- Testing
- BKM120
- Where
- Brazil
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients
The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation…
- Trial name
- SYMTECH01 (NCT06385587)
- Testing
- Oleena
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Aptar Digital Health
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Pancreatic Ductal Adenocarcinoma, Gastric Cancer
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
- Trial name
- NCT06710756
- Testing
- [203Pb]Pb-PSV359, [212Pb]Pb-PSV359
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Perspective Therapeutics
Head and Neck Squamous Cell Carcinoma
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
The primary objective of this clinical study is to compare the pharmacokinetic parameters of drugs RPH-002 and Erbitux® after a single intravenous administration, as well as to evaluate the safety of drug RPH-002 in comparison…
- Trial name
- NCT07435311
- Testing
- RPH-002, Erbitux®, cisplatin
- Where
- 18 sites in Russia
- Volunteers
- 118 people
- Sponsor
- R-Pharm
Cervical Cancer
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive
This study is a multi-center, prospective, open-label, single-arm phase II clinical study to evaluate the efficacy, safety and immunogenicity of GB226 in treatment of recurrent or metastatic cervical cancer patients with PD-L1…
- Trial name
- NCT03808857
- Testing
- GB226
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Genor Biopharma Co., Ltd.
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
HPV Infection, Lesion Cervix
Clinical Trial to Evaluate Papilocare® Gel Efficacy Into Repairment of Cervical Lesions Caused by HPV
Clinical Trial phase III, randomized, double-blind, parallel-group, controlled using lactic acid gel to evaluate the efficacy of Papilocare gel in the repair of cervical lesions caused by HPV. The study is divided into two parts.
- Trial name
- PAPILOCAN (NCT04210336)
- Testing
- PAPILOCARE, LACTIC ACID GEL
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Procare Health Iberia S.L.
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03234712
- Testing
- ABBV-321
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- AbbVie
Head and Neck Cancer
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003328
- Testing
- porfiromycin, radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Thyroid Neoplasms
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize…
- Trial name
- NCT05994365
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cervical Cancer Screening
Comparison of the Hologic Genius Digital Diagnostics System With the Liquid-based Cytology (LBC) Manual Microscopy
Quality assurance of the laboratory examinations. Prospective non-interventional study with ThinPrep slides collected during the German Co-Screening Program and routinely sent to the lab to prospectively evaluate the clinical…
- Trial name
- NCT04965857
- Testing
- Hologic's Genius Digital Diagnostics System
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- Hologic Deutschland GmbH
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Head and Neck Cancer
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or…
- Trial name
- NCT01577173
- Testing
- MEHD7945A, cetuximab
- Where
- 51 sites in United States, Australia and 9 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic…
- Trial name
- NCT05798819
- Testing
- GLS-010, paclitaxel, cisplatin
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Human Papillomavirus Infection, Self Sampling
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc. developed a safe and comfortable vaginal self-sampling device "Hygeia Touch Self Sampling Kit for Women" to self-collect the vaginal discharge sample for high-risk Human Papillomavirus (hrHPV) detection.
- Conditions
- Human Papillomavirus Infection, Self Sampling, Vaginal Discharge
- Trial name
- NCT04472377
- Testing
- Self sampling kit for collecting discharge from vaginal fornix
- Where
- 3 sites in Taiwan
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Hygeia Touch Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.